NCT04902040 2026-03-18
Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies
M.D. Anderson Cancer Center
Phase 1/2 Terminated
Clinical Trials
6 trialsNCT01664182 2022-06-07
Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT01198158 2019-03-06
Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy
National Cancer Institute (NCI)
Phase 3 Terminated
NCT00378703 2018-11-14
Bevacizumab, Sorafenib Tosylate, and Temsirolimus in Treating Patients With Metastatic Kidney Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT01727089 2018-08-28
Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00126490 2015-06-30
Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer
National Cancer Institute (NCI)
Phase 2 Completed